Exosome Therapy for Parkinson's Disease

📖 Wiki Page

therapeutic1882 wordssynced 2026-04-02

Exosome Therapy for Parkinson's Disease

Overview

flowchart TD Exosome_Therapy_for_Parkinson_["Exosome Therapy for Parkinsons Disease"] Exosome_Therapy_for_Parkinson_["Parkinson"] Exosome_Therapy_for_Parkinson_ -->|"related to"| Exosome_Therapy_for_Parkinson_ style Exosome_Therapy_for_Parkinson_ fill:#81c784,stroke:#333,color:#000 Exosome_Therapy_for_Parkinson_["table"] Exosome_Therapy_for_Parkinson_ -->|"related to"| Exosome_Therapy_for_Parkinson_ style Exosome_Therapy_for_Parkinson_ fill:#81c784,stroke:#333,color:#000 Exosome_Therapy_for_Parkinson_["class"] Exosome_Therapy_for_Parkinson_ -->|"related to"| Exosome_Therapy_for_Parkinson_ style Exosome_Therapy_for_Parkinson_ fill:#81c784,stroke:#333,color:#000 style Exosome_Therapy_for_Parkinson_ fill:#4fc3f7,stroke:#333,color:#000

...

Exosome Therapy for Parkinson's Disease

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Exosome Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">miRNA</td>
<td>Target</td>
</tr>
<tr>
<td class="label">miR-124</td>
<td>Neuroinflammation</td>
</tr>
<tr>
<td class="label">miR-7</td>
<td>Alpha-synuclein</td>
</tr>
<tr>
<td class="label">miR-153</td>
<td>Neuroprotection</td>
</tr>
<tr>
<td class="label">miR-29 family</td>
<td>Apoptosis</td>
</tr>
<tr>
<td class="label">miR-124-3p</td>
<td>Mitochondrial function</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommended Range</td>
</tr>
<tr>
<td class="label">Particle dose</td>
<td>1-10 × 10¹⁰ exosomes</td>
</tr>
<tr>
<td class="label">Volume per injection</td>
<td>50-200 muL</td>
</tr>
<tr>
<td class="label">Injection rate</td>
<td>0.5-2 muL/min</td>
</tr>
<tr>
<td class="label">Number of targets</td>
<td>2-4 per hemisphere</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT05427080</td>
<td>Phase 1/2</td>
</tr>
<tr>
<td class="label">NCT05335304</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">NCT04815625</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT04388982</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">NCT04919838</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">NCT05558648</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>MSC Therapy</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Cell survival, immunomodulation, trophic support</td>
</tr>
<tr>
<td class="label">Tumor risk</td>
<td>Potential for abnormal proliferation</td>
</tr>
<tr>
<td class="label">Immune rejection</td>
<td>Allogeneic cells may be rejected</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Limited cell expansion</td>
</tr>
<tr>
<td class="label">Storage</td>
<td>Cryopreservation challenges</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>Limited without modification</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>iPSC Neurons</td>
</tr>
<tr>
<td class="label">Integration</td>
<td>May integrate into circuitry</td>
</tr>
<tr>
<td class="label">Maturation</td>
<td>Variable differentiation</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>Surgical implantation</td>
</tr>
<tr>
<td class="label">Function</td>
<td>Replace lost neurons</td>
</tr>
<tr>
<td class="label">Timeline</td>
<td>Months for effects</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>AAV-GDNF/AAV-NTN</td>
</tr>
<tr>
<td class="label">Expression duration</td>
<td>Years (single dose)</td>
</tr>
<tr>
<td class="label">Reversibility</td>
<td>Not easily reversible</td>
</tr>
<tr>
<td class="label">Dosing control</td>
<td>Fixed expression</td>
</tr>
<tr>
<td class="label">Immune response</td>
<td>Viral capsid immunity</td>
</tr>
<tr>
<td class="label">Manufacturing</td>
<td>Complex viral production</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Method</td>
</tr>
<tr>
<td class="label">Particle size</td>
<td>NTA, DLS</td>
</tr>
<tr>
<td class="label">Particle concentration</td>
<td>NTA</td>
</tr>
<tr>
<td class="label">Marker expression</td>
<td>Flow cytometry</td>
</tr>
<tr>
<td class="label">Purity</td>
<td>Protein:particle ratio</td>
</tr>
<tr>
<td class="label">Sterility</td>
<td>Endotoxin, culture</td>
</tr>
<tr>
<td class="label">Identity</td>
<td>Cargo quantification</td>
</tr>
</table>

Exosome therapy for Parkinson's disease (PD) represents a cutting-edge approach that leverages extracellular vesicles (EVs) as natural delivery vehicles for therapeutic cargo to the brain. These nanoscale vesicles (30-150 nm) are secreted by various cell types and can cross the [blood-brain barrier](/entities/blood-brain-barrier), making them attractive carriers for delivering neuroprotective and restorative proteins to dopaminergic [neurons](/entities/neurons) in the [substantia nigra](/mechanisms/parkinsons-disease-selective-substantia-nigra-vulnerability).[@deng2019]

While general exosome therapy pages exist, PD-specific applications require detailed coverage of cargo options (GDNF, CDNF, microRNAs, siRNA), delivery methods optimized for deep brain structures, and direct comparison to cell therapy approaches. This page consolidates the current state of exosome-based therapeutics specifically for Parkinson's disease treatment.

Exosome Biology and Parkinson's Disease Relevance

Pathophysiological Rationale

Parkinson's disease is characterized by progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to motor symptoms (tremor, bradykinesia, rigidity) and non-motor symptoms (sleep disorders, autonomic dysfunction, cognitive decline). The pathological hallmarks include:

Lewy bodies: Intracellular inclusions composed primarily of misfolded [alpha-synuclein](/proteins/alpha-synuclein) aggregates
Lewy neurites: Degenerative neurites containing phosphorylated tau and alpha-synuclein
Neuroinflammation: Chronic activation of microglia contributing to neuronal loss
Mitochondrial dysfunction: Impaired energy metabolism and increased oxidative stress

Exosomes participate in the spread of alpha-synuclein pathology through the brain, but they can also be engineered to deliver therapeutic cargo that counters these pathological processes. The bidirectional nature of exosome biology in PD provides both a challenge and an opportunity for therapeutic development.[@stuendl2016]

Exosome-Mediated Alpha-Synuclein Propagation

Endogenous exosomes from neurons and glial cells can contain and transfer pathological alpha-synuclein between brain regions, contributing to disease progression. However, this same mechanism can be exploited:

Seedcompetent exosomes: Contain oligomeric alpha-synuclein that can template misfolding in recipient cells

Clearing exosomes: Engineered exosomes can absorb and sequester toxic species

Therapeutic cargo delivery: Exosomes can deliver proteins, RNAs, or small molecules that enhance neuronal survival

Neuroinflammation Modulation

PD-associated neuroinflammation involves persistent activation of microglia and astrocytes. MSC-derived exosomes contain anti-inflammatory molecules that can:

Suppress pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6)
Promote anti-inflammatory cytokine secretion (IL-10, TGF-β)
Modulate microglial phenotype from M1 (pro-inflammatory) to M2 (protective)
Reduce astrogliosis and preserve neuronal microenvironment[@drommelschmidt2017]

Therapeutic Cargo Options

GDNF (Glial Cell Line-Derived Neurotrophic Factor)

GDNF is one of the most potent neurotrophic factors for dopaminergic neurons, promoting their survival, function, and regeneration. Delivery via exosomes addresses historical challenges with direct GDNF infusion.

Mechanism of Action:

Binds to GFRα1 receptor on dopaminergic neurons
Activates RET tyrosine kinase signaling
Triggers PI3K/Akt (cell survival), MAPK/ERK (differentiation), and PLCγ (calcium signaling) pathways

Exosome-Based Advantages:

Sustained release of GDNF from exosome cargo
Enhanced BBB penetration compared to direct protein delivery
Reduced immunogenicity compared to viral gene therapy
Tunable dosing through repeat administration

Preclinical Evidence:

MSC-derived exosomes loaded with GDNF show enhanced dopaminergic neuron protection in MPTP mouse models
Combination of MSC exosomes with GDNF overexpression shows synergistic effects in vitro[@yong2019]

CDNF (Cerebral Dopamine Neurotrophic Factor)

CDNF is a neurotrophic factor with high affinity for dopaminergic neurons and distinct mechanism from GDNF. It provides neuroprotection through:

Endoplasmic reticulum stress reduction
Unfolded protein response modulation
Autophagy enhancement
Direct dopaminergic neuron protection

Exosome Delivery:

CDNF-loaded exosomes show promise in 6-OHDA rat models of PD
Combination with MSC-derived exosomes provides additional anti-inflammatory benefits
Superior to direct CDNF infusion in terms of distribution and sustained release[@voutilainen2015]

Clinical Status:

[CDNF Therapy for Parkinson's Disease](/therapeutics/cdnf-therapy-parkinsons) page covers human trials
Phase 1/2 trials ongoing with intraparenchymal delivery
Exosome-encapsulated CDNF remains at preclinical stage

microRNAs (miRNAs)

MicroRNAs delivered via exosomes can modulate gene expression in recipient neurons to promote survival and function.

Key miRNAs for PD:

Loading Methods:

Endogenous loading through cellular overexpression
Electroporation for siRNA/miRNA loading
Lipid-mediated transfection
Exosome surface display of miRNA "sponges"[@kojima2018]

siRNA (Small Interfering RNA)

siRNA can be used to knock down expression of genes that contribute to PD pathogenesis:

SNCA: Reduce alpha-synuclein production
LRRK2: Target gain-of-function mutations (G2019S)
GBA: Reduce glucocerebrosidase-related pathology
Parkin/PINK1: Enhance mitophagy in damaged neurons

Delivery Considerations:

siRNA requires efficient loading into exosomes
Chemical modifications enhance stability
Targeting ligands improve delivery to specific cell types
Combination with neurotrophic factors provides synergistic benefits

Delivery Methods

Systemic Administration

Intravenous (IV) Delivery:

Most common route for clinical translation
Requires targeting modifications for brain delivery
Surface engineering with brain-targeting ligands (rabies virus glycoprotein peptide, angiopep-2)
Dose: Typically 1-10 × 10¹⁰ particles per kg

Intranasal Delivery:

Direct nose-to-brain pathway bypasses BBB
Faster onset of action
Lower systemic exposure
Suitable for repeated dosing
[Exosome Delivery via Nasal Route](/ideas/delivery-exosome-nasal) page covers details

Direct Brain Delivery

Intraparenchymal Injection:

Stereotactic injection to substantia nigra/putamen
Higher local concentrations achievable
Requires surgical procedure
Used in clinical trials (NCT05427080)

Intrathecal Delivery:

Injection into cerebrospinal fluid
Distributes throughout CNS
Useful for reaching multiple brain regions
Requires repeated administrations

Optimized Approaches for PD

Targeted Substantia Nigra Delivery:

Stereotactic targeting using MRI guidance
Bilateral injection often required
CED (convection-enhanced delivery) improves distribution
Real-time imaging for verification

Delivery Parameters:

Clinical Trials Status

Active and Recruiting Trials

Completed Trials

Emerging Trials (2026)

First-in-human trials of exosome-encapsulated GDNF for PD expected
iPSC-derived exosomes with neurotrophic cargo entering clinical testing
Targeted exosomes with brain-penetrating peptides in preclinical development[@matsumoto2020]

Biomarkers for Treatment Response

Neuroimaging:

DaTscan (dopamine transporter imaging)
PET with FDG (glucose metabolism)
MRI with neuromelanin imaging

Fluid Biomarkers:

Neurofilament light chain (NfL) in CSF/serum
Alpha-synuclein seeding assays
Inflammatory cytokines (IL-6, TNF-α)
Neurotrophic factor levels (BDNF, GDNF)

Comparison to Cell Therapy Approaches

Mesenchymal Stem Cell (MSC) Therapy

iPSC-Derived Dopaminergic Neuron Therapy

Direct Viral Gene Therapy

Hybrid Approaches

Exosome-Producing Cells:

Genetically engineered cells that secrete therapeutic exosomes
Can be implanted (cell therapy + exosome hybrid)
Provides sustained exosome release in vivo
Example: GDNF-secreting MSCs

Exosome-Enhanced Cell Therapy:

Combine MSC transplantation with exosome co-administration
MSC provide local signaling, exosomes deliver specific cargo
Synergistic neuroprotection

Manufacturing and Quality Control

Exosome Production

Cell Source Selection:

Umbilical cord-derived MSCs (UC-MSCs)
Bone marrow-derived MSCs
iPSC-derived mesenchymal cells
Engineered cell lines

Production Methods:

Traditional 2D culture (scalability limited)
3D bioreactor systems (enhanced yield)
Hollow fiber bioreactors (clinical scale)

Isolation Techniques:

Ultracentrifugation (gold standard)
Size-exclusion chromatography
Tangential flow filtration
Immunoaffinity capture

Characterization Requirements

Regulatory Considerations

FDA guidance for cell-derived extracellular vesicles in development
EMA has specific guidelines for ATMPs (Advanced Therapy Medicinal Products)
Exosomes classified as biological product with specific CMC requirements
IND-enabling studies require GMP-grade manufacturing

Challenges and Future Directions

Current Challenges

Cargo Loading Efficiency

Optimize loading methods for different cargo types
Maintain cargo integrity during loading
Achieve therapeutic dosing

Targeting Specificity

Enhance brain targeting while reducing off-target
Achieve substantia nigra-specific delivery
Reduce peripheral organ accumulation

Dosing Regimens

Establish optimal dose and frequency
Determine treatment duration
Identify biomarkers for response

Manufacturing Scale-Up

Consistent lot-to-lot production
Cost-effective manufacturing
Quality control at scale

Emerging Innovations

Brain-penetrating exosomes: Engineered with novel peptides for enhanced BBB crossing
Stimulus-responsive exosomes: Activated by specific brain conditions
Theranostic exosomes: Combined therapeutic and diagnostic functions
Personalized exosomes: Patient-derived cells for individualized therapy
Gene-edited exosomes: CRISPR cargo for precise genetic modulation

External Links

[ClinicalTrials.gov - Exosome Parkinson's](https://clinicaltrials.gov)
[ISEV Guidelines for Extracellular Vesicle Research](https://www.isev.org/)
[Michael J. Fox Foundation - Therapeutic Strategies](https://www.michaeljfox.org/)
[Parkinson's Foundation - Research Updates](https://www.parkinson.org/)

References

[Deng et al., MSC exosomes for neurodegenerative disease (2019) (2019)](https://doi.org/10.1016/j.stem.2019.02.012)

[Stuendl et al., Induction of alpha-synuclein seed formation by exosomes (2016) (2016)](https://doi.org/10.1038/nm.4193)

[Drommelschmidt et al., Mesenchymal stem cell-derived exosomes (2017) (2017)](https://doi.org/10.1186/s12987-017-0062-5)

[Yong et al., Exosomes as therapeutic carriers for neurodegenerative diseases (2019) (2019)](https://doi.org/10.1016/j.jconrel.2019.02.027)

[Voutilainen et al., CDNF protects dopaminergic neurons in vivo (2015) (2015)](https://doi.org/10.1016/j.expneurol.2015.03.021)

[Kojima et al., Designer exosomes for targeted drug delivery (2018) (2018)](https://doi.org/10.1038/ncomms14750)

[Matsumoto et al., Clinical potential of exosome therapy (2020) (2020)](https://doi.org/10.1038/s41582-020-0370-0)

📖 View canonical wiki page →

Exosome Therapy for Parkinson's Disease

Exosome Therapy for Parkinson's Disease

Overview

Exosome Therapy for Parkinson's Disease

Overview

Exosome Biology and Parkinson's Disease Relevance

Pathophysiological Rationale

Exosome-Mediated Alpha-Synuclein Propagation

Neuroinflammation Modulation

Therapeutic Cargo Options

GDNF (Glial Cell Line-Derived Neurotrophic Factor)

CDNF (Cerebral Dopamine Neurotrophic Factor)

microRNAs (miRNAs)

siRNA (Small Interfering RNA)

Delivery Methods

Systemic Administration

Direct Brain Delivery

Optimized Approaches for PD

Clinical Trials Status

Active and Recruiting Trials

Completed Trials

Emerging Trials (2026)

Biomarkers for Treatment Response

Comparison to Cell Therapy Approaches

Mesenchymal Stem Cell (MSC) Therapy

iPSC-Derived Dopaminergic Neuron Therapy

Direct Viral Gene Therapy

Hybrid Approaches

Manufacturing and Quality Control

Exosome Production

Characterization Requirements

Regulatory Considerations

Challenges and Future Directions

Current Challenges

Emerging Innovations

See Also

External Links

References